Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 4/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4312678 | 0.88 | HTR2C (0.41) | HTR2CHTR6HTR1ASLC6A2 | |
| SCHEMBL4322400 | 0.88 | TDP1 (0.43) | HTR2CHTR1A | |
| SCHEMBL6046287 | 0.88 | CCNT1 (0.42) | HTR2CHTR6CCNT1CDK9 | |
| SCHEMBL4314845 | 0.86 | HTR2C (0.47) | HTR2CHTR6HTR1ASLC6A2 | |
| SCHEMBL7469509 | 0.82 | HTR2C (0.46) | HTR2CHTR6HTR1ASLC6A2 | |
| SCHEMBL4319475 | 0.82 | HTR2C (0.42) | HTR2CHTR6SOS1HTR1ASLC6A2 | |
| SCHEMBL4313594 | 0.81 | KCNH2 (0.35) | HTR2CHTR6HTR1ASLC6A2 | |
| SCHEMBL4320202 | 0.81 | HTR2C (0.50) | HTR2CHTR6HTR1ASLC6A2 | |
| SCHEMBL2639856 | 0.80 | HTR1A (0.46) | HTR6HTR1ASLC6A2 | |
| SCHEMBL4313464 | 0.80 | HTR1A (0.46) | HTR2CHTR6HTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534794-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2009-05-19 | — | — | US | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | HTR2C 1/4885HTR6 9/4885SOS1 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.